International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

Triclabendazole: The Drug of Choice against Fascioliasis Disease

Shashikant B. Kate*[1], S. B. Chavan[1], S. K. Mahajan[2]
[1] *Pharmaceutical Quality Assurance Department, MGV's Pharmacy College, Panchavati, Nashik, Maharashtra-422003, India.*
[2] *Pharmaceutical Chemistry Department, MGV's Pharmacy College, Panchavati, Nashik, Maharashtra-422003, India.*

Date of Submission: 15-07-2021 Date of Acceptance: 31-07-2021

ABSTRACT: Triclabendazole drug is associate with anthelmintic principally use to manage of the fluke, fluke, in sheepand cattle. Fasciolosis is caused by trematodes happiness to the genus Fasciola. Triclabendazole has been the drug of option to treat fluke infection in placental for >20 year, thanks to its high activity against adult and juvenile flukes. additional recently, it's been used with success to treat human fasciolosis. within the past, infection was restricted to specific and typical geographical areas however is currently widespread throughout the global, with human cases being more and more reportable from Europe, from Africa and Asia. As a consequence, human fasciolosis ought to be thought-about as a zoonotic disease of major world and regional importance. Humans become infected when consumption of contaminated food or water. fasciolosis is difficult to diagnose as several symptoms are like e.g. fever, abdominal pain and eating disorder. Triclabendazole drug was accepted for human use in Egypt in 1997 and in France in 2002 and a donation plan for the treatment of fasciolosis in endemic countries was afterwards established by the manufacturer and administered by the World Health Organization (WHO).

KEY WORDS: Triclabendazole, anthelmintic activity, fascioliasis, antimicrobial activity, carcinogenesis.

I. INTRODUCTION

Triclabendazoledrughas been theof selection for the treatment of liver fluke infections in placental for over twenty yearscurrently additional recently, it has been used to treathuman cases of fasciolosis.[1] Resistance to triclabendazole drug 1st discovered in farm animals inAustralia in the Nineteen Nineties and since then has been reportable range of European countries.[2] Fascioliasis is thought-about to be one of the most wide unfold foodborne fluke infections (Figure 1).[3, 4] thought-about a neglected tropical malady,[4, 5] human fasciolosis happens often times wherever consumption of wide aquatic vegetables is common or through contaminated water, notably in Bolivia, Peru, China, Cuba, Asian nation and Vietnam and Egypt.[6] Triclabendazole drug is a chlorinated benzimidazole derivatives. Compared with alternative fasciolicides it is outstanding for its higher efficaciousnessagainst each immature stages and adult forms of the worm at the same time.

The triclabendazole drug is effective against each acute migratory and chronic infections in cattle and in sheep given in single doses of 12 mg/kg and 10 mg/kg severally.[7] Triclabendazole drug prove to be extraordinarily safe for animal use. It is presently the drug of selection in the treatment of placental in Australia and alternative countries. The 1st winning human trial of triclabendazole drug was conducted in 1988; thereafter limited human trial has been reportable. The drug was either given in single dose of 10-12 mg/kg or in 2 doses 12-48 hours apart.[7]

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

Figure. 1: Worldwide distribution of fascioliasis according to the WHO, based on data for the latest year available.

II. CLINICAL PHARMACOLOGY

Diagnosis of fascioliasis:

Fascioliasis is difficult to diagnose, as several clinical options of the disease (e.g. gastrointestinal symptoms and eosinophilia) are non-specific.[10] Diagnosis is especially supported a mixture of clinical symptomatology (the science that studies the symptoms of diseases), laboratory evaluations, imaging (most normally ultrasound of computerized tomography scanning), serologic testing or coprologic tests detection of Fasciola spp. eggs in stool or small intestine aspirates, mistreatment for instance the Kato–Katz technique.[9,10] Detection of Fasciola spp. Eggs, whereas providing a definitive designation, is taken into account to be potential solely in chronic disease and acute fasciolosis remain additional to spot,[10,11] though medical science is additional helpful and imaging could also be additional sensitive and specific than in chronic disease.[11]All around distribution of fascioliasis according to the World Health Organization (WHO), based on data for the latest year available is shown in figure 1.[3]

Treatment of fascioliasis:

The treatment of human fasciolosis is predicated on the use of anthelminthic agent to kill flukes complemented by symptomatic treatment to alleviate abdominal pain, and probably the use of antispasmodics to treat biliary hurting, which can result once dead or dying flukes accumulate within the biliary ducts and cause voidance obstruction.[9] The life cycle of Fasciola Hepatica parasite is shown in figure 2.[19]

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781



Figure. 2: Fasciola Hepatica life cycle.

III. TRICLABENDAZOLE

Drug profile:

Empiricalformula:$C_{14}H_9Cl_3N_2OS$

Molecularformula: 359.66 g/mol

Physiochemicalproperties: White crystalline solid, Soluble in cyclohexanone, tetrahydrofuran, acetone, iso-propanol, n-octanol, and methanol and slightly soluble in dichloro-methane, xylene, ethyl acetate, chloroform, toluene; insoluble in water, hexane.



Figure. 3: Triclabendazole Structure.

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

Triclabendazole(6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole) is a benzimidazole derivative of ampholytic character shown in figure 3. It was originally developed and marketed by Ciba as Fasinex to treat fascioliasis in domestic livestock and has been in veterinary use since 1883. Following termination of commercial production of bithionol, development of triclabendazole drug for human use was initiated in the 1990s via a collaboration between the World Health Organization(WHO) and Ciba.

Mechanism of action of triclabendazole:

Triclabendazole drug could be a narrow-spectrum agent and is exclusive among benzimidazoles in its extremely specific activity against Fasciola spp. and Paragonimus spp., with lowest activity against nematodes, cestodes, or alternative trematodes.

Like alternative benzimidazoles derivatives, the mechanism of action of triclabendazole drug results from inhibition of tubule formation.[12] The β-tubulin macromolecule of F. hepatica exhibits species-specific macromolecule changesat position 82 (glutamic acid) andposition 91 (threonine), that are distinctive amo ng nematodes and cestodes.These substitutions seem to cause the fluke β-tubulin to adopt a three-dimensional structure that's comparatively unaccommodating to alternative benzimidazoles derivatives, that are flat or L-shaped.[17] Triclabendazole drug exhibit a nonplanar U-shaped configuration that seems to be unambiguously suited to binding to fluke β-tubulin.[12]

Additionally, triclabendazole-sulfoxide, the active matter of triclabendazole drug, has been shown to disturb the connective tissue of each mature and immature stages of F. hepatica.[14] Moreover, it's additionally a potent matter of macromolecule synthesis.[15] Though no resistance to triclabendazole drug has nonetheless been reportable in humans, resistance in veterinary use has become wide unfold since its original description in Australia.[16] Status to the drug seems to be increased by ketoconazole and methimazole among strains previously known to be resistant.[17, 18]

Recently, triclabendazole was reported to prohibit the action of adenylate cyclase in yeast and/or inhibit the connection of guanosine triphosphate-renin angiotensin system with adenylate cyclase.[19] Interestingly, Fasciola hepatica parasite has one of the extremelyhighoperative adenylate cyclase activities in biology and this activity is associated with the parasite's membrane fraction.[20] One of the first of triclabendazole-induced damage in Fasciola hepatica is tegumental blebbing and disruption of the tegumental ultrastructure.[21, 22, 23] If triclabendazole drug was shown to prohibit adenylate cyclase activity the effects of triclabendazole on the fluke's metabolism would likely be pleiotropic due to the second messenger function of cyclic adenosine monophosphate(cAMP) and its results on protein kinases, carbohydrate metabolism and movement.[20] These results suggest that an evaluation of the sensitivity of fluke adenylate cyclase to prohibition by triclabendazole drugmay be informative.In addition, an analysis of sequence polymorphisms in adenylate cyclase genes and/or guanosine triphosphate-renin angiotensin system(GTP-Ras) genes in resistant and susceptible fluke populations is warranted, to find out if there is any preference on thosesequences in resistant flukes.

New approaches to understanding the mode of action of triclabendazole drug:

The multiformity of studies reporting separate mechanisms of resistance to triclabendazole drug suggests that the (MOA) mode of action of triclabendazole drug and/or the effects on fluke metabolism are complicated, but the advent of new technologies could allow the target of triclabendazole drug to be solve in the upcoming time. One approach is affinity purification of the putative protein target whereby triclabendazole drug is immobilized to a solid support and a protein extract is passed over the column, followed by elution of any bound target proteins. This has resulted in recognition of protein targets against different types of drugs.[24,25, 59] However, these practiced seem best suited for situations where a high-affinity ligand attached a relatively abundant target protein.

A new-advances to understanding the mode of action of small molecules is the application of metabolomics, a whole organism assay approach that identifies metabolic perturbations in a cell upon exposure to drugs. This technique find out the metabolomic compounds via MS(mass spectrometry) or NMR(nuclear magnetic resonance) and has been applied to different drug studies in various parasites.[35] One such study with

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

the protozoan parasite Trypanosoma cruzi and the drug benznidazole revealed that metabolized benznidazole generated covalent adducts of redox active thiols such as glutathione and cysteine that were toxic to Trypanosoma cruzi.[36] This is in contrast with affinity purification studies that find out the orthologue, the bacterial homologue and aldo-keto-reductase as proteins that could bind immobilizedbenznidazole.[26]Thus, a combination of proposals may be required to fully characterize on-target and off-target effects of triclabendazole and to clearly define the mechanism of triclabendazole action.

IV. PHARMACODYNAMICS AND PHARMACOKINETICS

Triclabendazole drug could be a narrow-spectrum anthelminthic, with activity against worm genus (F. hepatica and F. gigantica) and Paragonimus spp. It's extremely effective against worm genus spp.at all stages of infection.[37, 38] The mechanism of action of triclabendazole drug has not been absolutely elucidated and will involve multiple targets, together with tegumental disruption via inhibition of microtubule-based processes or adenylate cyclase activity.[31]

The sulphoxide matter seems to possess a delayed however less attackable impact on parasite motility than triclabendazole itself, and it's probable that the drug acts mainly through this matter, that is essentially predominant in human plasma following pre-systemic biotransformation of triclabendazole.[32, 33, 34] As a result, pharmacokinetic investigations have relied chiefly on the determination of plasma concentrations of the sulphoxide matter.

Pharmacokinetics when oral administration of one dose of 10 mg/kg triclabendazole drug with a 560-kcal meal to patients with fasciolosis, mean peak plasma concentrations (Cmax) for triclabendazole drug, the sulfone sulfoxide and metabolites were 1.166µmol/L, 2.296µmol/L and 38.6µmol/L, severally. The area under curve (AUC) for triclabendazole drug, the sulfoxide and sulfone metabolites were 5.72 µmol.h/L, 38.6 µmol.h/L, and 30.5µmol.h/L, severally.[35]

Absorption of triclabendazole:

Following oral administration of one dose of triclabendazole drug at ten mg/kg with a 560-kcal meal to patients with fasciolosis, the median T-max for the parent compound and therefore the sulfoxide matter was three to four hours.

Impact of Food: C-max and AUC (Area Under Curve) of triclabendazole and sulfoxide matter inflated so 3-fold and 2-fold severally once triclabendazole drug was administered as one dose at 10
mg/kg with a meal containing a complete of roughly 560-kcal (consisting of two cups of sugared white occasional, a roll with cheese, and a roll with butter and jam). Additionally, the sulfoxide matter T-max inflated from a pair of hours within the fasted state to four hours within the fed state.[34]

Distribution of triclabendazole:

The apparent volume of distribution (Vd) of the sulfoxide matter in fed patients is or so one L/kg. Protein-binding of triclabendazole drug, sulfoxide matter and sulfone matter in human plasma was 99.7%, 98.4% and 98.8% severally.[35]

Elimination of triclabendazole:

The plasma elimination half-life (t1/2) of triclabendazole drug, the sulfoxide and sulfone metabolites in humans is 8, 14, and 11 hours respectively.[35]

Metabolism of triclabendazole:

Based on in vitro studies, triclabendazole drug is primarily metabolized by CYP1A2 (approximately 64%) into its active sulfoxide matter and to a lesser extent by the CYP2C9 (Cytochrome P2C9), CYP2C19 (Cytochrome P450), CYP2D6 (Cytochrome P2D6), CYP3A (Cytochrome P3A), and FMO(Flavin-containing mono-oxygenase).

This sulfoxide matter is more metabolized primarily by CYP2C9 (Cytochrome P2C9) to the active sulfone matter and to a lesser extent by CYP1A1 (Cytochrome P1A2), CYP1A2 (Cytochrome P1A2), CYP1B1 (Cytochrome P1B1), CYP2C19 (Cytochrome P2C19), CYP2D6 (Cytochrome P2D6) and CYP3A4 (Cytochrome P3A4), invitro.[41, 43,44]

In figure 4; proposed mechanisms of triclabendazole resistance in Fasciola hepatica is given. (A) Starting studies focused on the putative target of triclabendazole drug, namely beta-tubulin, although no mutations conferring resistance have been identified. (B) Several studies suggest that triclabendazole is a substrate for membrane transporters such as P-glycoprotein. Their activity is increased in triclabendazole drug resistant flukes which may reduce the intracellular concentration of

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

the drug at its site of action. (C) Metabolism of active forms of triclabendazole to comparatively inert metabolites are increased in triclabendazole-resistant flukes.[44]

Excretion of triclabendazole:

There is absence of excretion data on humans. However, in animals, the drug is essentially excreted via the biliary tract within the faecal matter (90%), at the side of the sulfoxide and sulfone matter. But 100% of associate in nursing oral dose is excreted within the body waste.[33]

Pharmacokinetic parameters were similar in healthy volunteers and fasciolosis patients.[37] Two open-label, non-randomized studies, one performed in South American country and therefore the alternative in Europe, compared administration beneath fed and abstinence conditions in fasciolosis patients, with similar leads to every study.

Absorption of triclabendazole drug was rapid: t-max [time to succeed in the most body fluid concentration] of 2-3 hours for the parent compound.[34] The mean most body fluid concentration (C-max) and median t-max of sulphoxide matter were inflated from a pair of hours (fasting) to 4 hours (fed) and 15.8µmol/L to 38.6µmol/L, severally. Overall, food resulted in regarding a pair of 2.2-fold increase within the United Self-Defense Force of Colombia of sulphoxide matter. The mean elimination half-life of the sulphoxide matter from plasma is or so 11 hours within the fed state.[34]

The improved exposure to the drug beneath fed conditions junction rectifier to a recommendation that triclabendazole to be administered with food. No excretion studies of triclabendazole drug were conducted in humans; but, in animals, the drug is essentially excreted via the biliary tract within the faeces (approximately 90%), at the side of the sulphoxide and later on the sulphones matter. But 100% of associate in nursing oral dose is excreted within the body waste.[33]

No significant questions of safety associated with drug–drug interactions were determined from clinical studies and post-marketing safety knowledge. This might doubtless be attributed to the single-dose administration of triclabendazole drug.

V. EFFICACY AND SAFETY STUDIES IN HUMANS

Triclabendazole drug treatment of human fasciolosis has been studied over amount of virtually thirty year employing a type of doses and regimens during a big selection of geographic areas.

Most studied were non-comparative, given the shortage of effective various treatment which use of placebo controls wouldn't be thought of ethically acceptable (although one placebo-controlled study with nitazoxanide in fasciolosis has been conducted).[37] Two comparatively recent studies compared triclabendazole with artemisinin derivatives.[39, 40]

VI. RESISTANCE TO TRICLABENDAZOLE

To understand however resistance to triclabendazole drug could develop, it's necessary to know the mechanism of drug action. Triclabendazole drug could be a benzimidazole spinoff and, by analogy with what's notable regarding alternative benzimid azole medicine, would possibly it would be anticipated that triclabendazole might bind to the β-tubulin molecule then disrupt microtubule-based processes. Proof in support of this concept has come back from morphological studies on the cutis, vitellaria and testicle, following treatment with the active sulphoxide matter.[2]

For instance, there's inhibition of cell division within the vitelline andspermatogenic cells; disruption of transport processes within the cutis (the outer layer of a trematode), that ends up in more and more severe injury of the tegumental surface, culminating within the total loss of the tegument.[49] Loss of tubulin immunostaining within the tegumental cytoplasm has conjointly been determined.[50]

The results counsel that the microtubules have disappeared that, in turn, would forestall the movement of secretory bodies from the cell bodies to the tegumental surface. This method is significant for the upkeep of the integrity of the surface membrane and its disruption would make a case for the severe morphological changes seen.[2]

Triclabendazole drug resistance is threat to livestock production systems:

Fasciola species (Fasciola hepatica, Fasciola gigantica), also called as liver fluke parasites, are transmitted allover the world in sheep and cattle and their prevalence in some areas is so largein scale that serious clinical disease, termed

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

fasciolosis, arises.[43,44]Globally, fasciolosis due to both fluke species is conventionally thought to cause manufacturing losses of over US$3 billion.[45] The benzimidazole derivative triclabendazole, one of the highly used drugto control fasciolosis, was first introduced in the early 1980s as a flukicide to treat and control acute and chronic fasciolosis in ruminants.[47, 48]

It had high efficacy (>98%) more than 98% against adult flukes and, moreeffective, unique efficacy in case of early immature and immature flukes. Other single flukicides only target more mature fluke ranging in age from 8-14 weeks.[46] As a result, triclabendazole (TCBZ) rapidly became the drug of choice for treating fluke infections, especially in sheep, as it was safe and allowed producers the relative luxury of not having to test for the stage of fluke exist in their livestock.[48, 49] This over dependent on triclabendazole to treat sheep and, to a lesser extent cattle, has resulted in selection for fluke resistant to triclabendazole.[48, 49, 62] The status of triclabendazole-resistance in Fasciola hepatica has been analysed. This review will focus on the current status of triclabendazole resistanceglobally, the possible mechanisms of action of the drug, the present knowledge of the genetics of resistance, the prospects for future control of liver fluke infections and the application of anIPM (integrated parasite management) plan to manage fasciolosis.

Current global status of triclabendazole drug resistancein livestock:

Since the first arrival of triclabendazole drug resistance in Fasciola hepatica triclabendazole resistance has compromised fluke control in livestock in 11 countries or regions. Resistance has likely seemed due to a normally poor understanding of liver fluke biology by farmers and confounding factors such as wrong dosing; inappropriate product choice and lack of testing for efficacy.[50, 51, 52] The giant frequency of triclabendazole drug use, successfully triclabendazole mono-therapy with no anthelmintic rotation, was a major contributing factor towards the development of triclabendazole resistance.[53, 54] Since triclabendazole drug is not a persistent chemical, resistance was likely due to head selected in contrast to tail selection observed with roundworms.[55]

The majorpractice used to find out triclabendazole drug resistance in the field has been the Faecal Egg Count Reduction Test (FECRT), with the suggested post-treatment sample collection time point at 21 days.[56, 57]Another studies using experimental infections have used 14 days for post-treatment sample collection which may not grantenough time for all eggs from dead parasites to be passed out of the gall bladder and be excreted.[58, 59] The use of the FECRT and the new coproantigen enzyme-linked immunosorbent assay (c-ELISA), in the form ofa Coproantigen Reduction Test (CRT), is now flattering usual research practice but has yet to be consistently used in the field. As triclabendazole drug kills entire stages of a fluke infection in the host animal, a significant decrease (depletion) (>95%) of egg count or coproantigen should take place in a susceptible fluke population using an oral triclabendazole drug formulation. However, when adult flukicides are tested, the egg counts andcoproantigen levels may not be reduced to zero at the time of re-testing (21 days post-treatment), even in defense less population, since young parasites not targeted by the adult flukicide will eventually mature and release eggs or coproantigens. Various studies have reveal that the signal in the c-ELISA is correlated to fluke numbers and could probably be used to designate the relative level of fluke infection (low, moderate, high), allowing the targeted treatment of animals but further work is need to validate the c-ELISA under field conditions.[44] The bulk milk tank ELISA is also used to find out fluke infections; however, this procedure only find out antibodies to whole fluke antigen and, since antibodies can persist following treatment, this ELISA can't be used to evaluate drug efficacy against Fasciola hepatica[44, 21].

Prior to 2011, peer-reviewed reports of triclabendazole drug resistance were historically reported in livestock on only six country in Australia, Scotland, Wales, the Netherlands, Spain and the Republic of Ireland.[21] Since then, triclabendazole drug resistance has been reliably reported in sheep or cattle on a further country in N.Ireland, Peru, Wales, Australia, Scotland, New Zealand, and Argentina.[57] Three human cases of triclabendazole drug resistance are discussed below. In total, cases of triclabendazole drug resistance have been reported on at least country. Several non-peer reviewed cases of triclabendazole treatment failure on-farm (possible triclabendazole resistance) are not listed.

Human cases of triclabendazole drug resistant fluke infections:

Triclabendazole drug is also the drug of choice for treating fasciolosis in humans and it is

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

possible that triclabendazole drug resistance fluke populations, selected in livestock, could pose a zoonotic risk to human health, especially in areas (country) such as Peru and Bolivia where there is a very high incidence of human infections. The first incidence of triclabendazole drug treatment failure in humans was reported in a livestock farmer in the Netherlands, with furtherrecent reports of 4 cases from Chile, one case from Turkey and 7 cases from Peru.[63] Clearly, triclabendazole drug resistance zoonotic infections are a serious emerging issue.

Mechanism of triclabendazole resistance:

To understand the mechanism of resistance to triclabendazole drug have used the sligo isolate (light micrographs of Fasciola hepatica) of trematode worm. This isolate has been shown to be immune to the action of triclabendazole in vivo, at each the adult and juvenile stages.[61] Flukes from this isolate conjointly resist the action of triclabendazole in vitro, even at abnormally high concentrations.[63]

Mechanisms concerned within the development of resistance to alternative anthelmintic may end up from changes within the target molecule, in drug uptake/efflux mechanisms and in drug metabolism.[62] With relevancy changes within the target molecule, the target is probable to be β-tubulin, however tubulin staining isn't abolished by triclabendazole drug within the resistant isolate.[61] However, in nematodes benzimidazole resistance has been joined to choice of a β- tubulin isotype with essential amino acid to amino acid substitution at 167thposition or at 200thposition.[63]

It is attainable that triclabendazole drug resistance could arise within the Fasciola hepatica from an identical variant choice mechanism.

Several being species encrypt quite iso- sort.

Expected peptide sequence comparisons reveal little variable regions between them, most notably at the C-terminus.[2]

β-tubulin isotypes that area unit expressed in adult fluke are known and their writing regions are absolutely sequenced.

Comparison of the β-tubulin sequences from vulnerable and resistant fluke isolates indicate that they contain identical amino acids at the positions concerned in roundworm benzimidazole resistance.However, some organic compound variations are noted at alternative positions however whether or not these organic compound changes area unit relevant to the resistant composition or area unit because of traditional gene variation within the genes coding these isotypes remains to be determined and lots of a lot of sequences from individual triclabendazole-susceptible triclabendazole and resistant triclabendazole flukes can have to be compelled to be obtained. Studies area unit afoot in each adult and juvenile fluke to spot the drug-sensitive isotypes by localizing the sites of expression of the varied the varied the varied, and so determinative that isotypes area unit expressed in area unit that are severely discontinuous in triclabendazole drug treatment.

At the molecular level, structural studies have shown that the residues that area unit variable in benzimidazole-resistant organismsarea unit brought along to make a cluster throughout the folding of the β-tubulin super-molecule. These studies conjointly indicated that the cluster of "sensitive" residues wasn't on the surface of the molecule, raising the question of however may the drug access this region?

Molecular modeling studies victimization sequences from the Fasciola hepatica and therefore the roundworm Haemonchus contortus are accustomed propose an answer.[64]

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781



Figure. 4: Proposed mechanisms of triclabendazole resistance in Fasciola hepatica.

VII. SAFETY AND TOLERABILITY OF TRICLABENDAZOLE

Based on the obtainable knowledge (data), triclabendazole drug seems to be tolerated within the treatment of fasciolosis. The foremost common adverse events related to treatment seem to be associated with the expulsion of dead or dying flukes from the hepatobiliary system.

These adverse events (AEs), characterized as biliary intestinal colic, embrace abdominal, hypochondrial and epigastric pain, usually in the midst of sweating, in some cases with associated clogging jaundice and elevations in body fluid levels of internal organ enzymes, mostordinarily base-forming enzyme.[66, 69]

The temporal order of those events (biliary intestinal colic symptoms tend to occur 3-7 days post-therapy, with elevations of internal organ enzymes, typically occurring around seven days post-treatment), indicates that parasite expulsion is that the possibly cause instead of an on the spot relationship to triclabendazole. Triclabendazole C-max happens 4-10hour post-ingestion, whereas expulsion of parasites usually happens 48hour when dosing.[66] Among alternative adverse events (AEs) ordinarily according throughout the studies, urticaria, itch and rash is also associated with fasciolosis, as they ordinarily occur in infected patients. alternative comparatively common adverse events (AEs) were headache, vertigo and light headedness.

VIII. DOSAGE AND ADMINISTRATION OF TRICLABENDAZOLE

The counseled dose of triclabendazole drug is a pair of doses of 10 mg/kg given 12 hours apart in patients half dozen years old-time and older. The 250 mg tablets square measure functionally scored and severable into 2 equal halves of one hundred 25 mg. If the indefinite quantity can't be adjusted precisely, around the dose upwards.[35] Take triclabendazole orally with food. Triclabendazole tablets are often engulfed whole or divided into half and brought with water or crushed and administered with applesauce. The crushed pill mixed with applesauce is stable for up to four hours.[35]

Triclabendazole comes as a tablet to take by mouth. It is usually taken every 12 hours for 2 doses. Take triclabendazole tablet with food. Follow the directions on given prescription label carefully, and ask doctor or pharmacist to explain any part you do not understand. Take triclabendazole doses exactly as directed. Do not take more or less of it than prescribed by doctor.

IX. CONTRAINDICATIONS

Triclabendazole drug is contraindicated in patients with known hypersensitivity to triclabendazole and/or to alternative benzimidazole derivatives or to any of the excipients use in triclabendazole.[35]

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

X. ADVERSE EFECTS OF TRICLABENDAZOLE

Adverse effects of triclabendazole drug discovered in ≥2% (less than or equal to) of patients who received a complete of 10 or 20mg/kg of triclabendazole for fasciolosis treatment.[35] Adverse effects such as; abdominal pain, sweating, vertigo, nausea, urticaria, vomiting, headache, dyspnea, pruritus, asthenia, system hurting, cough, faded appetency, chest pain, pyrexia, jaundice, chest discomfort, diarrhea.[35] Triclabendazole seems to be remarkably safe. Adverse events, once they have occurred, are gentle, short lived, and restricted to abdominal pain, headache, nausea, and fatigue.[70] Abdominal pain, lasting but five days, was according by 21.5% of patients receiving triclabendazole, 5mg/kg daily for three days, 6.7% receiving 10mg/kg double daily for at some point, and 31.3% receiving one dose of 10mg/kg.[67]

A recently over trial within the Bolivianaltiplano according similar findings.[70] The abdominal pain is usually settled within the right higher quadrant, is eased by oral spasmolytics, and has been attributed to the expulsion of dead or dying worms from the hepatobiliary system into the internal organ tract.

Adverse effects discovered in but or capable a pair of patients who received a complete of 10mg/kgof triclabendazole drug were constipation, biliary intestinal colic, arthralgia, back pain, spinal pain, and chromaturia. Some adverse effects related to triclabendazole drug treatment in fasciolosis, e.g. abdominal pain, biliary intestinal colic, and jaundice, may well be secondary to the infection and should be a lot of frequent and/or severe in patients with a significant worm burden.[35]

The security profile of triclabendazole 20mg/kg in divided doses in an exceedingly non-hepatic parasitic infection was typically kind of like the security profile in fasciolosis, apart from a lower incidence of post-treatment abdominal pain.[35]

XI. DRUG INTERACTIONS

Effect of triclabendazole drug on CYP2C19 (Cytochrome P2C19) substrates no specific clinical drug interaction studies are conducted for triclabendazole. However, in vitro knowledge counsel the potential for raised plasma concentrations of CYP2C19 (Cytochrome P2C19) substrates with concomitant use of triclabendazole. The potential elevation in concentrations of concomitantly used CYP2C19 (Cytochrome P2C19) substrates is anticipated to be transient supported the short elimination half-life and short treatment length of triclabendazole.[39]

Triclabendazole drug and its sulfoxide and sulfone metabolites have the potential to inhibit CYP1A2 (Cytochrome P1A2), CYP2A6 (Cytochrome P2A6), CYP2B6 (Cytochrome P2B6), CYP2C8 (Cytochrome P2C8), CYP2C9 (Cytochrome P2C9), CYP2C19 (Cytochrome P2C19), CYP2D6 (Cytochrome P2D6), and CYP3A (Cytochrome P3A) at clinically relevant plasma concentrations, with the best potential of inhibition on CYP2C19 (Cytochrome P2C19). No in vitro studies were conducted to assess the flexibility of triclabendazole and its metabolites to induce CYP (Cytochrome P) enzymes. No in vitro studies were conducted to assess the flexibility oftriclabendazole and its metabolites to induce or inhibit transporters.

Using triclabendazole with any of the following medicines is not recommended by physician. Drugs that are interact with triclabendazole they are as follows, bepridil, cisapride, dronedarone, mesoridazine, pimozide, piperaquine, saquinavir, sparfloxacin.

XII. MICROBIOLOGY OF TRICLABENDAZOLE

The mechanism by which triclabendazole exhibits its effect against Fasciola species is not fully elucidated. Studies in vitro and/or in infected animals suggest that triclabendazole and its active metabolites (sulfoxide and sulfone) are absorbed by the tegument of the immature and mature worms, leading to a decrease of the resting membrane potential, inhibition of tubulin function as well as protein and enzyme synthesis. These metabolic disturbances are associated with inhibition of motility, disruption of the surface as well as ultrastructure that includes inhibition of spermatogenesis and vitelline cells.[35]

Antimicrobial activity:

Triclabendazole drug and its metabolites square measure active against the immature and mature worms of trematode worm and Fasciola gigantica.[35]

XIII. NONCLINICAL TOXICOLOGY OF TRICLABENDAZOLE

Mutagenesis:

No genotoxic potential was noted for triclabendazole drug tested in an exceedingly battery of half dozen genotoxicity in

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

vitro and in vivo assays that embrace a microorganism reverse mutation assay, body aberration assays, and a micronucleus assay.[35]

Impairment of Fertility:

No drug-related effects on generative performance, sexual activity ratios or fertility indices are noted in an exceedingly second generation generative and biological process toxicity study in rats.

The animals were treated with up to 75ppm triclabendazole via diet, amounting to a mean daily intake of 7.3 mg/kg/day (approximately 0.1 times the MRHD supported body area comparison) for amount of 10days, including a 12-day sexual activity amount starting on day 62 of dosing and continued till the offspring were weaned.[35]

Animal Toxicology and/or Pharmacology

Dietary administration of triclabendazole drug at a dose of 39 mg/kg/day (1.1-times the MRHD supported body area comparison) was related to a transient increase within the QT and QTc intervals on weeks five and nine in some dogs in an exceedingly 13-week study leading to QT (QTc) intervals of 212-227 (318-338) millisecond in the 39mg/kg dose cluster (adjusted) compared to 190-193 (280-297) millisecond in controls. At Week-13, no statistically vital variations were noted between the treatment and management teams.[35]

When dogs were administered triclabendazole at one dose of 40 or 100mg/kg (1.1 or 2.7 times the MRHD supported body area comparison), increase in QTc intervals was discovered leading to QTc intervals of 217-247 millisecond compared to a traditional (historical control) of 193-231 millisecond. However, plasma levels of the sulfone matter in dogs (which is assumed to mediate QTc prolongation) was concerning 100-500 times the plasma level of the sulfone matter measured in human plasma.[35]

Within the 13-week study in hound dogs, slight anemia in the middle of bottom will increase in erythrocyte and cell organ red cell counts were discovered at 39 mg/kg/day (1.1 times the MRHD supported body area comparison) preponderantly at week nine of dosing.[35]

XIV. CLINICAL STUDIES

An open label, randomized (irregular) trial of triclabendazole drug, conducted in Vietnam compared the effectiveness of triclabendazole (two 10mg/kg doses given 12 hours apart with food) to oral artesunate (4 mg/kg, given once daily for ten days).[7,35] 100 patients (age range: 9-74 years) with acute symptomatic fasciolosis were irregular, 50 in every treatment cluster.

At three months when treatment, 92% and 76% (difference 16%; 95% CI, p=0.035) of patients within the triclabendazole and artesunate arms severally, according no clinical symptoms. The clinical development program of triclabendazole for the treatment of fasciolosis enclosed half dozen nonrandomized, open label studies performed in Cuba, Bolivia, Peru, Chile, and Asian country in an exceedingly total of 245 adult and pediatric patients with stool-confirmed fasciolosis. All studies were similar in style.[35] The studied triclabendazole drug doses ranged from 5mg/kg to 20mg/kg administered on days 1-3.[7] Cure was outlined as absence of Fasciola eggs within the stool supported the Kato-Katz technique at Day 60 in patientswere positive at baseline. Across these studies, there was a finding of a dose response. Specifically, the Day 60 cure rate was highest (95.5%; 95% CI) for the 20mg/kg dose, that was given in a pair of divided doses, followed by cure rates of half a mile (95% CI), 80% (95% CI), and 50% (95% CI) within the 15mg/kg, 10 mg/kg, and five mg/kg dose teams, severally. The 5mg/kg, 10 mg/kg, and 15mg/kg dosing regimens don't seem to be approved. These rates were considerably above that calculable from patients receiving associate degree inadequate, non-triclabendazole treatment in an exceedingly separate study (22%; 95 CI.[35]

XV. USES OF TRICLABENDAZOLE:

Triclabendazole drug is used to treat fascioliasis (an infection, usually in the liver and bile ducts, caused by flat worms [liver flukes]) in adults and children 6 years of age and older. Triclabendazole is in a class of medications called anthelmintics oranthelmintics (medicine use to kill worms). It works by killing the flat worms.

Pediatric Use

Safety and effectiveness of triclabendazole has been established in pediatric patients aged 6 years and older. Safety and effectiveness of triclabendazole in pediatric patients below the age

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

of 6 years have not been established.

Geriatric Use

Clinical studies of triclabendazole did not include sufficient numbers of patients aged 65 and over to determine whether the old age patients respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the higher frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy.

Renal Impairment

Triclabendazole has not been studied in patients with renal impairment.

Hepatic Impairment

Triclabendazole has not been studied in patients with hepatic impairment.

XVI. RESULITS AND DISCUSSION

Human fasciolosis has been according on all occupied continents however is most typical or different in bound regions, notably specific areas of South American nation, Bolivia, Egypt, Asian country and Vietnam. Despite the worldwide distribution of fasciolosis, treatment choices were restricted before the event of triclabendazole drug, and stay thus, as no alternative therapies have incontestable similar, adequate efficacy against fasciolosis. On the premise of studies within the 1990s performed by the WHO unitedly with Ciba, studies by the Egyptian government and subsequent revealed studies, case series and case reports, triclabendazole is very effective within the treatment of human fasciolosis.

The first studies established that a 10mg/kg single dose, given postprandially, is typically effective, however, patients have to be compelled to be followed up for confirmation of clinical improvement. Just in case of treatment failure with a 10mg/kg single dose, 2 further doses of 10mg/kg are often given 12 to 24 minutes apart.

These studies were the premise of restrictive approvals in Egypt in 1997 and France in 2002 and square measure square measure within the current WHO recommendations. The recent approval by the USA authority recommends a complete dose of twenty mg/kg; this can be primarily based totally on newer studies.[69] Studies in pediatric patients counsel that identical treatment regimen to be utilized in youngsters of ≥6 year old and is well tolerated.[66] Triclabendazole drug has been shown in clinical studies to be effective within the treatment of chronic and acute types of fasciolosis and in each F. hepatica and F. gigantica infections. Triclabendazole treatment was typically well tolerated, with most adverse events in all probability associated with the expulsion of dead or dying flukes from the biliary tract. Though resistance to triclabendazole in placental infections is well established (as may well be expected following its intensive use in veterinary medicine), it seems to be rare and infrequent in human fasciolosis. Most clinical trials with triclabendazole drug within the treatment of human fasciolosis have utilized open-label, non-comparative styles (although in several studies, some irregular, completely different dose regimens were compared). This was in the main thanks to the dearth of effective active comparators. Moral issues preclude placebo controls in studies in fasciolosis, though one placebo-controlled study with nitazoxanide. During this study, solely 1/16 (6.25%) placebo-treated patients stopped discharge eggs at 90 day.This suggests that solely atiny low placebo response in many instances expected in fasciolosis which the employment of placebo controls in studies with triclabendazole drug would be are of very little worth.

The sole prospective irregular comparative trial with triclabendazole, that used artesunate as a comparator, was uncommon therein egg counts weren't practice (patients seemed to have the acute type of fascioliasis) and complete response rates at 60 day were low for each compound (for reasons mentioned previously) however higher with triclabendazole than artesunate.[36] Triclabendazole is that the solely treatment for fasciolosis treatment problem resolve by the WHO and also the Pan yank Health Organization, and is that the drug of alternative treatment problem resolve by the USA Centers for illness management and interference.Following initial approvals in Egypt and France, a donation program for triclabendazole for the treatment of fasciolosis in endemic countries, beneath the steering of the WHO's department of management of neglected tropical diseases, was established.

Between 2006 and 2016, the manufacturer

International Journal of Pharmaceutical Research and Applications
Volume 6, Issue 4 July-Aug 2021, pp: 750-765 www.ijprajournal.com ISSN: 2249-7781

(Novartis) given triclabendazole drug to the WHO as treatment for 1.15 million patients.

The recent approval by the USA authority makes the drug withoutdelay obtainable within the USA and additional demonstrates the continuing importance of triclabendazole drug for the treatment.

As regards the mechanism of triclabendazole drug resistance, work thus far indicates that altered drug uptake and metabolism could also be a lot of necessary than any changes to the probable target (namely, tubulin).[69]Reduced drug uptake, followed by quicker drug metabolism, would severely limit the number of triclabendazole reaching its target. A lot of remains to be learned concerning the identity and expression of effluence pumps and also the role of metabolic pathways.

ACKNOWLEDGEMENTS

The authors wish to thank the MGV's Pharmacy College Panchavati, Nashik, Maharashtra-422003, Savitribai Phule Pune University, India.

REFERENCES

[1]. Preetam Gandhia, Esther K. Schmitta, Chien-Wei Chenb, Sanjay Samantrayc, Vinay Kumar Venishettyc and David Hughesa. Triclabendazole in the treatment of human fascioliasis: a review. Trans R Soc Trop Med Hyg 2019; 113: 797–804.

[2]. G.P. Brennan, I. Fairweather, A. Trudgett, E. Hoey, McCoy, M. McConville, M. Meaney, M. Robinson, N. McFerran, L. Ryan, C. Lanusse, L. Mottier, L. Alvarez, H. Solana, G. Virkel, P.M. Brophy, et al. Review: Understanding triclabendazole resistance. Experimental and Molecular Pathology 2007;82:104-9.

[3]. Furst T, Keiser J, Utzinger J. Global burden of human food borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(3):210-221.

[4]. World Health Organization. Neglected tropical diseases. https:// www.who.int/foodborne_trematode_infections/en/ [accessed 25 April 2021].

[5]. Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research. Tropical disease priority review vouchers. Guidance for industry. October 2016. https://www.fda.gov/media/72569/ download [accessed 28 April 2021].

[6]. Mas-Coma S, Bargues MD, Valero MA. Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures. Parasitology. 2018;145 (13 Special Issue):1665-1699.

[7]. Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control. WHO headquarters, Geneva, Switzerland 17–18 October 2006. 1-2.

[8]. Cabada MM, White AC Jr. New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis. 2012;25(5):518–522.

[9]. Mas-Coma S, Bargues MD, Valero MA. Diagnosis of human fascioliasis by stool and blood techniques: update for the present global scenario. Parasitology. 2014;141(14):1918-1946.

[10]. Marcos LA, Tagle M, Terashima A et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg. 2008;78(2):222–227.

[11]. Fica A, Dabanch J, Farias C et al. Acute fascioliasis-clinical and epidemiological features of four patients in Chile. Clin Microbiol Infect. 2012;18(1):91–96.

[12]. Robinson MW, Hoey EM, Fairweather I, et al. Characterization of a beta-tubulin gene from the liver fluke, Fasciola hepatica. Int J Parasitol. 2001;31:1264-1268.

[13]. Kwa MS, Veenstra JG, Roos MH. Molecular characterization of beta-tubulin genes presents in benzimidazole-resistant populations of Haemonchus contortus. Mol Biochem Parasitol. 1993; 60:133-143.

[14]. Toner E, Brennan GP, McConvery F, et al. A transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology. 2010; 137:855-870.

[15]. Stitt AW, Fairweather I, Mackender RO. The effect of triclabendazole ("Fasinex") on protein synthesis by the liver fluke, Fasciola hepatica. Int J Parasitol. 1995; 25:421-429.

[16]. Overend DJ, Bowen FL. Resistance of Fasciola hepatica to triclabendazole. Aust Vet J. 1995; 72:275-276.

[17]. Devine C, Brennan GP, Lanusse CE, et al. Potentiation of triclabendazole action in vivo against a triclabendazole resistant isolate of Fasciola hepatica following its

coadministration with the metabolic inhibitor, ketoconazole. Vet Parasitol. 2012; 184:37-47.

[18]. Devine C, Brennan GP, Lanusse CE, et al. Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol Res 2010;106:1351-1363.

[19]. Lee YJ. The small molecule triclabendazole decreases the intracellular level of cyclic AMP and increases resistance to stress in Saccharomyces cerevisiae. PLoS ONE 2013;8, e64337

[20]. Mansour TE.Chemotherapy of parasitic worms: new biochemical strategies. Science. 1979;205:462-9.

[21]. Fairweather I.Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy? Vet. Parasitol 2011;180:133-143.

[22]. Stitt AW, Fairweather I.Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex). Parasitol. Res 1993;79:529-536.

[23]. Stitt AW, Fairweather I.The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology 1994;108:555-567.

[24]. Brehmer D. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell Proteomics 2004;3:490–500.

[25]. Argyrou A.Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 2006;45:13947–13953.

[26]. Trochine A. Trypanosoma cruzi chemical proteomics using immobilized 471 benznidazole. Exp. Parasitol 2014;140:33–8.

[27]. Creek DJ, Barrett MP.Determination of antiprotozoal drug mechanisms by metabolomics approaches. Parasitology 2014;141:83–92.

[28]. TrochineA.Benznidazole biotransformation and multiple targets in Trypanosoma 475 cruzi revealed by metabolomics. PLoS Negl Trop Dis 2014;8:e2844.

[29]. Keiser J, Engels D, Büscher G. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs. 2005;14(12):1513–1526.

[30]. Fairweather I. Triclabendazole progress report, 2005–2009: an advancement of learning? J Helminthol. 2009;83(2):139–150.

[31]. Kelley JM, Elliott TP, Beddoe Tetal. Current threat of triclabendazole resistance in Fasciola hepatica. Trends Parasitol. 2016;32(6):458–469.

[32]. Stitt AW, Fairweather I. The effect of the sulphoxide metabolite of triclabendazole (Fasinex®) on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology. 1994;108(5):555–567.

[33]. Hennessy DR, Lacey E, Steel JW et al. The kinetics of triclabendazole dispositionin sheep. J Vet Pharmacol Ther. 1987;10(1):64–72.

[34]. Lecaillon JB, Godbillon J, Campestrini J et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol. 1998;45(6):601–604.

[35]. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936:5-6.

[36]. I. Fairweathera, GP Brennana, REB Hannab, MW Robinsona, PJ Skucec. Review Drug resistance in liver flukes. IJS: Drugs and Drug Resistance 2020;12;39-59.

[37]. el-Tantawy WH, Salem HF, Mohammed Safwat NAS. Effect of fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects. Pharm World Sci. 2007;29(3):190–198.

[38]. Favennec L, Jave Ortiz J, Gargala G. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther.2003;17(2):265–270.

[39]. Hien T, Truong N T, Minh N Hetal. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam.AmJ. TropMedHyg.2008;78(3):388–392.

[40]. Keiser J, Sayed H, el-Ghanam M. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratoryphase-2trials.PLoSNeglTropDis.2011;5(9):e1285.

[41]. Stitt A.W., Fairweather I. Spermatogenesis in Fasciola hepatica: an ultrastructural comparison of the anthelmintic,

triclabendazole ("Fasinex") and the microtubule inhibitor, tubulozole. Invertebr. Reprod. Dev. 1992;22:139–150.

[42]. Robinson MW, Trudgett, A, Hoey, EM, Fairweather, I.Triclabendazole-resistantFasciolahepatica:β-tubulinandresponsetoinvitrotreatment with triclabendazole. Parasitology 2002;124:325–338.

[43]. Dargie JD.The impact on production and mechanisms of pathogenesis of trematode infections in cattle and sheep. Int. J. Parasitol. 1987;17:453-463.

[44]. Charlier J. Recent advances in the diagnosis, impact on production and prediction of Fasciola hepatica in cattle. Parasitology 2014;141:326-335.

[45]. SpithillTW.Chapter 15. Fasciola gigantica: epidemiology, control, immunology and molecular biology. In Fasciolosis 1999:465-525.

[46]. Fairweather I, BorayJC. Fasciolicides: efficacy, actions, resistance and its management. Vet. J. 1999;158:81-112.

[47]. Boray JC.Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Vet. Rec. 1983;113:315-317.

[48]. Fairweather I.Triclabendazole: new skills to unravel an oldenigma. J. Helminthol. 2005;79:227-234.

[49]. Brennan GP. Understanding triclabendazole resistance. Exp. Mol. Pathol. 2007;82:104 – 109.

[50]. Fairweather I.Liver fluke isolates: a question of provenance. Vet. Parasitol. 2011;176:1-8.

[51]. Fairweather I. Raising the bar on reporting 'triclabendazole resistance'. Vet. Rec. 2011;168:514-515.

[52]. Anon. Raising awareness of sustainable management of liver fluke in sheep. Vet. Rec. 2015;177:246.

[53]. Overend DJ, Bowen F.L.Resistance of Fasciola hepatica to triclabendazole. Aust. Vet. J. 1995;72:275-276.

[54]. Moll L.Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The Netherlands. Vet. Parasitol. 2001;91:153-158.

[55]. Le Jambre LF. Selection for anthelmintic resistance by macrocyclic lactones in Haemonchus contortus. Int. J. Parasitol. 1999;291;101-1111.

[56]. Wood I.B. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) second edition of guidelines for evaluating the efficacy of anthelmintics in ruminants (bovine, ovine, caprine). Vet. Parasitol. 1995;58:181-213.

[57]. Brockwell YM.Confirmation of Fasciola hepatica resistant to triclabendazole in naturally infected Australian beef and dairy cattle. Int. J. Parasitol: Drugs and Drug Res. 2014;4:48-54.

[58]. Flanagan AM.Comparison of two assays, a faecal egg count reduction test (FECRT) and a coproantigen reduction test (CRT), for the diagnosis of resistance to triclabendazole in Fasciola hepatica in sheep. Vet. Parasitol. 2011;176:170-176.

[59]. Flanagan AM.Standardization of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica. Vet. Parasitol. 2011;176:34-42.

[60]. Fox NJ.Predicting impacts of climate change on Fasciola hepatica risk. PloS ONE 2011;6:e16126.

[61]. Caminade C.Modelling recent and future climatic suitability for fasciolosis in Europe. Geospatial Health 2015;9:301-308.

[62]. Mas-Coma S.Fascioliasis and otherplant-borne trematode zoonoses. Int. J Parasitol. 2005;35:1255-1278.

[63]. Winkelhagen AJS.Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands. Emerg. Infect. Dis. 2012;18:1028–1029.

[64]. Gülhan B.Partial hepatectomy for the resistant Fasciola hepatica infection in a child. APSP J Case Rep. 2015;6:27

[65]. Kwa MS, Veenstra JG, Roos MH.Benzimidazole resistance in Haemonchus contortus is correlated with a severe mutation at amino acid 200 in beta-tubulin isotype1. Mol. Biochem. Parasitol. 1994;63:299–303.

[66]. Villegas F, Angles R, Barrientos Retal. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS Negl Trop Dis. 2012;6(8):e1720.

[67]. el-Morshedy H, Farghaly A, Sharaf S. Triclabendazole in the treatment of human fascioliasis: a community-based study. East Mediterr Health J. 1999;5(5):888–894

[68]. Lecaillon JB, Godbillon J, Campestrini J.

Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol. 1998;45:601-604.

[69]. el-Karaksy H, Hassanein B, Okasha S. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J Trop Pediatr. 1999;45:135-138.

[70]. Apt W, Aguilera X, Vega F. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg. 1995;52:532-535.